An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
Chinese participants meet the diagnosis of moderately to severely active Ulcerative colitis (UC)
Participants prescribed upadacitinib at discretion of their treating physicians based on sufficient consideration of benefits/risks for patients per local label
Participant must be an adult (≥ 18 years)
Participant must provide written authorization to use personal and/or health data prior to the entry into the study
You may not be if
Participant participating in any interventional trials
Participant with any contraindication to upadacitinib as listed on the local China label
Participant unwilling or unable to comply with the study requirements, including completion of patient reported outcome questionnaires
Clareo Health | An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
